GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VIA Pharmaceuticals Inc (GREY:VIAP) » Definitions » Interest Coverage

VIA Pharmaceuticals (VIA Pharmaceuticals) Interest Coverage : 0 (At Loss) (As of Dec. 2010)


View and export this data going back to 1998. Start your Free Trial

What is VIA Pharmaceuticals Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. VIA Pharmaceuticals's Operating Income for the three months ended in Dec. 2010 was $-0.89 Mil. VIA Pharmaceuticals's Interest Expense for the three months ended in Dec. 2010 was $-1.58 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for VIA Pharmaceuticals's Interest Coverage or its related term are showing as below:


VIAP's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 156.65
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


VIA Pharmaceuticals Interest Coverage Historical Data

The historical data trend for VIA Pharmaceuticals's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

VIA Pharmaceuticals Interest Coverage Chart

VIA Pharmaceuticals Annual Data
Trend Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A No Debt - - -

VIA Pharmaceuticals Quarterly Data
Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of VIA Pharmaceuticals's Interest Coverage

For the Biotechnology subindustry, VIA Pharmaceuticals's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VIA Pharmaceuticals's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VIA Pharmaceuticals's Interest Coverage distribution charts can be found below:

* The bar in red indicates where VIA Pharmaceuticals's Interest Coverage falls into.



VIA Pharmaceuticals Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

VIA Pharmaceuticals's Interest Coverage for the fiscal year that ended in Dec. 2010 is calculated as

Here, for the fiscal year that ended in Dec. 2010, VIA Pharmaceuticals's Interest Expense was $-3.56 Mil. Its Operating Income was $-5.91 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

VIA Pharmaceuticals did not have earnings to cover the interest expense.

VIA Pharmaceuticals's Interest Coverage for the quarter that ended in Dec. 2010 is calculated as

Here, for the three months ended in Dec. 2010, VIA Pharmaceuticals's Interest Expense was $-1.58 Mil. Its Operating Income was $-0.89 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

VIA Pharmaceuticals did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


VIA Pharmaceuticals  (GREY:VIAP) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


VIA Pharmaceuticals Interest Coverage Related Terms

Thank you for viewing the detailed overview of VIA Pharmaceuticals's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


VIA Pharmaceuticals (VIA Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
750 Battery Street, Suite 330, San Francisco, CA, USA, 94111
VIA Pharmaceuticals Inc is a development stage biotechnology company focuses on the development of small-molecule drugs to treat cardiovascular and metabolic diseases.
Executives
Fred B Craves director 750 BATTERY ST, STE 600, SAN FRANCISCO CA 94111
Bay City Capital Fund Iv, L.p. 10 percent owner 750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111
Bay City Capital Management Iv Llc 10 percent owner 750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111
Bay City Capital Fund Iv Co Invesment Fund Lp 10 percent owner 750 BATTERY ST STE 400, SAN FRANCISCO CA 94111
Bay City Capital Llc 10 percent owner 750 BATTERY STREET STE 400, SAN FRANCISCO CA 94111
Douglas B Given director C/O NEORX CORP, 410 WEST HARRISON ST, SEATTLE WA 98119
Karen Steil Wright officer: V.P. ? Finance, Controller 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Lawrence Kenneth Cohen director, officer: CEO and President 750 BATTERY STREET, SUITE 330 SAN FRANCISCO CA 94111
Richard L Anderson director 14031 216TH WAY NE, WOODINVILLE WA 98072
Mark Bagnall director 3876 BAY CENTER PLACE, HAYWARD CA 94545
Rebecca Taub officer: SVP, Research & Development 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Adeoye Y Olukotun officer: Chief Medical Officer 3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
Deerfield Special Situations Fund International Ltd 10 percent owner, other: Possible Member of 10% Group BISON COURT, ROAD TOWN, TORTOLA D8 -
Deerfield Special Situations Fund, L.p. 10 percent owner, other: Possible Member of 10% Group 780 3RD AVENUE, 37TH FLOOR, NEW YORK NY 10017
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017

VIA Pharmaceuticals (VIA Pharmaceuticals) Headlines

From GuruFocus